Research Admin CITI Biostatistics Manuscripts PGMC Innovation & Incubation Centre(SRIIC) Clinical Research Division (CRD) Sophisticated Instrumentation Lab (SIL) Visiting Professors Conferences Organised
Infrastructure Academics/Training Consultancy Services Clinical Research Projects Clinical Research Team Contact
Infrastructure Academics/Training Services Projects Team Contact
SRIIC - Norms & Guidelines Incubatees Contact
Team Contact
CRMSCR CPTMR CISM CGC CDFMET CBN CLSDMP CECCRe SCOPE CSS Internationally Recognised Research Centres
Ph.D D.Sc.
Research Promotion Policy Resource Mobilisation Policy IPR Policy Consultancy Policy Research Promotion Schemes Innovation Ecosystem
Extramural Government Funded Extramural - NGO Funded Consultancy Projects
Publications Patents Copyrights
Faculty of Clinical Research Courses Offered Contact

Clinical Research - Ongoing Projects

S.NO Principal Investigator Study / Project Title Sponsor
1 Dr.Padmasani Venkataramanan KEMHRC/PERT/1 (Pertussis Surveillance). Surveillance of Pertussis among hospitalized infants in India. KEM Hospital
2 Dr. R. Sathianathan Study No: R092670PSY3015 “A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation” Johnson & Johnson Pvt. Ltd.
3 Dr. Muralidharan EFC14875/The SCORED Trial “A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function”.  Sanofi Synthelabo (India) Pvt. Ltd.
4  Dr. Vaishnavi To evaluate the safety and tolerability of HCLX 031706 in Healthy adult volunteers: Randomized, open label, two arm clinical study  The Himalaya Drug Company
5  Dr. R. Sathianathan Study No. MYL-1802N-1001 “A Randomized, Multicenter, Multiple-dose, Two-treatment, Parallel, Steady State Bioequivalence Study of Paliperidone palmitate ER Injectable Suspension (546 mg; Mylan) and INVEGA TRINZA® ER Injectable Suspension (546 mg; Janssen Pharmaceuticals, Inc) in subjects with Schizophrenia.  Cliantha Research Ltd.
6 Dr. Shanthi Vijayaraghavan MYL-SLD-4001 Multicenter, Open Label, Prospective, Phase IV Interventional Study in Adult Indian Patients to Evaluate the Safety and Efficacy of MyHep LVIRTM (ledipasvir/sofosbuvir, Fixed Dose Combination) in HCV genotype 1 infection and the combination of MyHepTM (sofosbuvir) and MyDeklaTM (daclatasvir) in HCV genotype 3 infection.  Siro Clinpharm Pvt. Ltd.
7 Dr. Shanthi Vijayaraghavan MYL-MYV-4001 “A multicenter, open label, single arm, prospective, Phase IV study to evaluate the safety and efficacy of MyHep All™ (Sofosbuvir/ Velpatasvir, fixed dose combination) in Indian Adult patients with chronic Hepatitis C Virus (HCV) infection”. Siro Clinpharm Pvt. Ltd.
8 Dr. Jovita Martin Protocol No:: 0384-18, Version 3.0, Dated 01 May 2018 “A randomized, open label, two arm, single dose, crossover bioequivalence study of Ayana Pharma’s Doxorubicin Hydrochloride Liposome injection (LC-101) (Investigational Product) and the US Reference Standard Doxorubicin Hydrochloride Liposome Injection (Sun Pharma Global), in subjects with Ovarian Cancer  Ayana Pharma Ltd.
9 Dr. Shriraam Mahadevan Protocol Number: NN9536-4373 Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity. Novo Nordisk India Pvt. Ltd.
10 Dr. Hemamalini Glycemic Index testing of fibre rich white rice varieties (Payasa) MDJ Agrofibre Pvt Ltd. (Payasa High Fibre EnergyA)